CM
MRNA icon

Capula Management’s Moderna MRNA Stock Holding History

Capula Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,700
Closed -$589K – 478
2023
Q3 		$589K Sell
5,700
-13,300
-70% -$1.48M 0.01% 306
2023
Q2 		$2.31M Sell
19,000
-36,000
-65% -$4.8M 0.06% 132
2023
Q1 		$8.45M Buy
+55,000
New +$9.07M 0.1% 173

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Capula Management's MRNA Position: Q2 2026 in Review

Capula Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 14,500 shares — an estimated $737K sold.

Capula Management first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $962K in Q3 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Capula Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Capula Management sold 14,500 Moderna shares in Q2 2026, an estimated $737K.
  • Capula Management first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
  • Capula Management's Moderna position peaked at $962K in Q3 2022.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.